Sean Brimacombe, MD
Orthopaedic Surgery · Phoenix, AZNPI 1427105048
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $64,500 of the $107,191 with a category attached, or 60.2%. Amgen accounts for 85.0% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2019 at $87,288 and has fallen 99.4% since, to $528 in 2025. Among orthopaedic surgery clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 264 payments — averaging $406.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$91K
- Heron Therapeutics, Inc.$6K
- Smith+Nephew$4K
- UCB SA$3K
- Mimedx Group, Inc.$1K
- Radius Health, Inc.$597
- plus $1K from 21 others
What the payments were for
- Consulting fees$22,26121%
- Speaking & faculty fees$64,50060%
- Travel & lodging$13,70813%
- Food & beverage$6,6986%
- Education$240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 152 | $91,082 |
| Heron Therapeutics, Inc. | 16 | $5,648 |
| Smith+Nephew | 17 | $4,351 |
| UCB SA | 1 | $2,760 |
| Mimedx Group, Inc. | 10 | $1,346 |
| Radius Health, Inc. | 36 | $597 |
| UCB, Inc. | 3 | $296 |
| Kerecis Limited | 1 | $204 |
| Davol Inc. | 1 | $139 |
| AstraZeneca | 1 | $122 |
| Biosense Webster, Inc. | 1 | $118 |
| KCI USA, Inc. | 4 | $83 |
| Team_makena_llc | 2 | $77 |
| Stryker | 1 | $42 |
| Johnson & Johnson | 1 | $35 |
| Abiomed | 1 | $32 |
| Misonix Inc | 1 | $30 |
| Organogenesis Inc. | 2 | $29 |
| Sanofi-aventis U.S. LLC | 2 | $26 |
| Integra Lifesciences Corporation | 2 | $25 |
| Musculoskeletal Transplant Foundation Inc. | 3 | $25 |
| Urgo Medical North America, LLC | 1 | $24 |
| Mallinckrodt Enterprises LLC | 1 | $24 |
| Polarityte, Inc. | 1 | $21 |
| Solventum Corporation | 1 | $19 |
| Acera Surgical, Inc. | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolia$46,825
- EVENITY$45,970
- HTX-011$5,224
- Repatha$4,950
- Santyl$4,023
- Kerecis SurgiClose$816
- Kerecis GraftGuide$204
- LYNPARZA$122
- Tymlos$119
- Carto 3 System$118
How this compares
$107,191 in reported general payments places this provider in the 90th percentile of 377 orthopaedic surgery providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TymlosAbaloparatide | 60 | $171,488 |
| ForteoTeriparatide | 19 | $77,419 |
| ProliaDenosumab | 36 | $61,969 |
| SsdSilver Sulfadiazine | 27 | $486 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 13 | $444 |
| CefuroximeCefuroxime Axetil | 24 | $396 |
| Alendronate Sodium | 53 | $377 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 26 | $296 |
| Doxycycline Monohydrate | 23 | $285 |
| Silver Sulfadiazine | 22 | $277 |
| Ciprofloxacin Hcl | 27 | $258 |
| Cefadroxil | 26 | $226 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Radius Health, Inc.Tymlos | $597 | $171,48860 claims |
| AmgenProlia | $91,082 | $61,96936 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 377 orthopaedic surgery providers in Arizona.
Other orthopaedic surgery in Phoenix
- Evan LedermanPhoenix$12M
- James ChowPhoenix$6.1M
- Michael McKeePhoenix$3.4M
- Henry ClarkePhoenix$1.9M
- Samuel HarmsenPhoenix$735K
- Anthony HedleyPhoenix$415K
- Matthew SeidelPhoenix$397K
- David OttPhoenix$380K
- Michael WilminkPhoenix$347K
- Judd CummingsPhoenix$269K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.